Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIS-102
- Development stage
- Unknown
- Lead developer
- Wuhan Hiteck Biological Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
VIS-102 (also known as HT006.2.2) is an investigational, next-generation modified recombinant human nerve growth factor (rhNGF) eye drop being developed for the treatment of neurotrophic keratitis (NK). Originally developed by Wuhan Hiteck Biological Pharma and licensed globally (excluding Greater China) to Visara (a subsidiary of NovaBridge Biosciences), VIS-102 incorporates targeted amino acid sequence modifications and formulation optimization designed to improve resistance to enzymatic degradation and maintain stability under refrigeration. This allows the therapy to be supplied in ready-to-use, single-dose units, potentially reducing the storage and administration burden compared to existing treatments. VIS-102 acts by targeting the nerve growth factor (NGF) pathway to restore corneal nerve function and promote corneal healing.
- Other names
- modified recombinant human nerve growth factormodified rhNGFrecombinant human nerve growth factor
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NGFR (p75NTR)
Beyond the preview
Go deeper on VIS-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIS-102.